News

Press Releases

AOA Dx Inc signs exclusive option agreement to commercialize cancer diagnosis technology from Professor Uri Saragovi, Senior Investigator with the Lady Davis Institute at the Jewish General Hospital and Professor at McGill University

January 4, 2021

AOA Dx Inc Files US Patent (No. 63,087427) for the identification of gangliosides as markers for ovarian cancer

January 4, 2021

RQRM Grant Awarded to technology licensed by AOA Dx Inc.

Prof. Uri Saragovi and Dr. Anne-Marie Mes-Masson were awarded a grant from the RQRM for initial tumor-ganglioside screening studies to enable early detection of cancers

January 4, 2021

McGill University’s Clinical Innovation Competition supports the development of Prof. Uri Saragovi’s research on ovarian cancer tumour markers. AOA Dx Inc to lead development and commercialization

January 4, 2021